Evaluation of committed and primitive cord blood progenitors after expansion on adipose stromal cells.
Andreeva ER., Andrianova IV., Gornostaeva AN., Gogiya BS., Buravkova LB.
Laboratory Study, published in Cell Tissue Res (2018) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Cell Tissue Res (2018)
- Country
- Germany
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 29327082
- DOI
- 10.1007/s00441-017-2766-x
Abstract (original English)
Umbilical cord blood mononuclear fraction is a valuable source of hematopoietic stem and progenitor cells (CB HSPCs). The rarity of this population is a serious limitation of its application in cell therapy. Ex vivo expansion enables to significantly amplify the number of hematopoietic precursors of different commitment. Here, we expand CB MNCs in co-culture with human adipose tissue-derived stromal cells (ASCs) to enrich HSPCs and describe phenotypic features of newly formed hematopoietic populations. The CD34 + -HSPCs demonstrated 6-fold enrichment with 9000 CFUs per 50 × 10 3 HSPCs on average. A part of the floating HSPCs were bearing lineage markers, while others were primitive precursors (CD133 - /CD34 + ). Among ASC-associated HSPCs, two subsets of cord blood-borne cells were revealed: СD90 + /СD45 - and СD90 + /СD45 + . The proportion of CD3 + /CD8 + and NK-T as well as CD25 + and HLA-DR + Т cells among СD90 + /СD45 - cells was significantly higher compared to MNCs and floating HSPCs. More than 80% of CD45 + /СD90 + HSPCs were identified as late primitive precursors (CD133 - /CD34 + ). Thus, CB MNC expansion in the presence of ASCs provides the generation of both lineage committed lymphoid progenitors and CD34 + /CD133 - primitive HSPCs. Substantially enriched with primitive precursors, ASC-associated HSPCs could be considered as a perspective tool for a long-term restor
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.